Arecor Therapeutics, EMV Capital, Creo Medical, hVIVO, DigitalBox, Ilika - Small Cap Week in Review

Описание: Arecor Therapeutics PLC (AIM:AREC) has teamed up with Sequel Med Tech to develop AT278, an ultra-concentrated insulin for pumps. Both firms are funding development, while a US$11 million royalty financing deal with Ligand Pharmaceuticals extends Arecor’s cash runway into 2027.

EMV Capital (AIM:EMVC) picked up assets from the collapsed Destiny Pharma, including phase 2 proven XF-73. The company aims to restart phase 3 trials, targeting the big US market for hospital infections with a low-cost model.

Creo Medical Group PLC (AIM:CREO, OTC:CMEOF) reported 40% revenue growth on stronger adoption of its Speedboat technology. A £25 million deal with Micro-Tech added cash, while SpydrBlade gained US clearance and new markets are opening up.

hVIVO PLC (AIM:HVO) booked £24 million in revenue, supported by a diversified mix of services, therapeutics and clients, and £3 million in EBITDA. It expects £47.00 million for the full year, with a return to growth forecast for 2026.

Digitalbox PLC (AIM:DBOX) saw page impressions rise 15% and reach up 30%, driving 12% revenue growth in the first half. On-platform revenue jumped to £400,000, while its social following soared to nearly 30 million.

Ilika PLC (AIM:IKA, OTCQX:ILIKF) launched its PRIMED programme to back solid-state battery development. Work with UK BIC and Jaguar Land Rover supports 50Ah A-Sample batteries and future large-scale production.

Follow us and subscribe on YouTube, our social channels and on proactiveinvestors.co.uk.